This article examines antipsychotic interactions with COVID-19 drugs, categorizing them as safe (e.g., remdesivir, baricitinib, anakinra), cautious (clozapine, baricitinib, favipiravir with specific antipsychotics), and concerning (chloroquine, hydroxychloroquine, azithromycin, lopinavir/ritonavir). Tocilizumab may affect antipsychotic metabolism, while olanzapine appears relatively safer with lopinavir/ritonavir. Consider potential QT prolongation and CYP interactions when prescribing antipsychotics to COVID-19 patients, following safety guidelines. This evidence concerns the gene PPIG and COVID-19.